TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

CYTK SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that Cytokinetics Investors Have Opportunity to Lead Class Action Lawsuit

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Faruqi & Faruqi, Llp
CYTK SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that Cytokinetics Investors Have Opportunity to Lead Class Action Lawsuit

Faruqi & Faruqi is investigating potential claims against Cytokinetics regarding misleading statements about their New Drug Application (NDA) submission for aficamten, alleging the company failed to disclose material risks related to regulatory process requirements.

Insights
CYTK   negative

The company is accused of making false and misleading statements about its drug approval timeline, potentially misleading investors and causing significant stock losses by omitting critical regulatory information about REMS submission